DOCSLIB.ORG

Progressive Normalization of Growth Hormone-Binding Protein and IGF-I Levels in Treated Growth Hormone-Deficient Children*

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Progressive Normalization of Growth Hormone-Binding Protein and IGF-I Levels in Treated Growth Hormone-Deficient Children* 0031-399819513706-0731$03.0010 PEDIATRIC RESEARCH Vol. 37, No. 6, 1995 Copyright O 1995 International Pediatric Research Foundation, Inc. Printed in U.S.A. Progressive Normalization of Growth Hormone-Binding Protein and IGF-I Levels in Treated Growth Hormone-Deficient Children* JULIANE LEGER, MICHELE NOEL, PAUL CZERNICHOW, AND MARIE-CATHERINE POSTEL-VINAY Department of Pediatric Endocrinology and Diabetes, Hopital Robert Debre' [J.L., M.N., P.C.] and INSERM Unite' 344, Molecular Endocrinology, Hopital Necker-Enfants Malades, Paris, France [M.-C.P.-V.] 'ACT The short- and long-term effects of hGH treatment on growth increase in serum IGF-I level was observed as soon as 1 wk of hormone (GH)-binding protein (GHBP) were examined in 18 hGH therapy, and after 3 mo, the mean IGF-I value was normal. prepubertal children, aged 1.5-10 y, with isolated idiopathic GH No correlation was found between the increase in GHBP, IGF-I deficiency. The patients were studied before and at regular levels, and the growth velocity at 12 and 24 mo of treatment. intervals during 24 mo of hGH therapy (0.6 IU/kg/wk, given These findings support the role of GH in the regulation of daily). Pretreatment GHBP values were low: 14.6 2 1.2% of GHBPIreceptor in man. The time course of the GH effect appears radioactivity (p < 0.0001 versus normal prepubertal children). to be progressive and variable. (Pediatr Res 37: 731-735,1995) After the first hGH injection, GHBP levels fell significantly at 6 h (8.2 2 1.3% of radioactivity) and then remained at basal level during the first week. Under hGH therapy, an increase in GHBP Abbreviations was observed, but it occurred at different times of treatment, from GH, growth hormone 1 to 12 mo, and the mean GHBP value became significantly GHBP, growth hormone-binding protein higher than the value before treatment after 12 mo of therapy. An BMI, body mass index Identification of the serum GHBP and demonstration that the the plasma GH binding activity. On one hand, GH is able to amino acid sequence of GHBP is identical to that of the increase GHBP levels, as was shown in children with GH extracellular domain of the membrane GH receptor have pro- deficiency (5, 6) and also in children with idiopathic short vided new tools to study GH action in man (1, 2). In clinical stature (7). On the other hand, absence of GH effect on GHBP research, measurement of serum GHBP is the only approach to has been reported in treated GH-deficient children (8). estimate the GH receptor because there are no accessible cells In this work, we have examined short-term and long-term in which GH receptors can be measured. In man, GHBP effects of hGH treatment in prepubertal children with isolated probably results from proteolytic cleavage of the membrane GH deficiency. GHBP was measured longitudinally before receptor as no specific mRNA for the short form of the GH treatment and during 24 mo after the beginning of GH therapy. receptor is detected in human tissues (3). The plasma GHBP Short-term effects of hGH may represent an important issue as level is believed to reflect the concentration of tissue GH they could be used to better predict response to hGH therapy in receptors. In animal models, GH receptors have been shown to physiopathologic situations. be modified in several pathologic situations (4). As membrane GH receptors are regulated by many factors, the level of METHODS plasma GHBP is expected to be under a multifactorial control. Among many factors, GH has been shown to play an Subjects and protocol. Eighteen prepubertal children (11 important role in the regulation of its receptors. However, a boys and 7 girls), aged 1.5-10 y (mean age: 5.6 + 2.9 y), with controversy has recently arisen concerning the effect of GH on isolated idiopathic GH deficiency, were studied before treat- ment and at regular intervals during the first 2 y of hGH therapy. GH deficiency was defined as subnormal GH re- Received September 8, 1994; accepted December 20, 1994. sponses to at least two provocative tests (peak GH < 10 p,g/L), Correspondence: Dr. M-C Postel-Vinay, INSERM Unit6 344, Faculti de Mtdecine which was chosen by the French Pituitary Agency for provid- Necker, 156 Rue de Vaugirard, 75730 Paris Cedex 15, France. * This work was presented in part at the Joint Meeting of LWPESESPE, San Francisco, ing hGH therapy. Recombinant hGH (Saizen, Serono Labora- June 1993 (Abstract 356). tories and Genotonorm, Kabi Pharmacia Laboratories) was given s.c. daily, at the dosage of 0.60 IU/kg/wk. All but four >6 pg/L, as previously reported (5); this was the case for all subjects were followed longitudinally for 2 y of treatment. blood samples collected 6 h after the first GH injection and for Patient 14 could not be followed after 6 mo of therapy, and one sample collected at 12 h. three patients (nos. 1, 8, and 11) were studied for 1 y only. None of the patients of the study group developed detectable Three patients (nos. 13, 17, and 18) entered puberty between GH antibodies as observed on the elution profiles from HPLC- 18 and 24 mo of the treatment; for that reason and for that time gel filtration of lZ51-h~~incubated with serum. The GH period, results for these patients were not included. Height and concentration was measured by immunoradiometric assay us- weight were measured before treatment and every 3 mo on ing polyclonal antibodies (Pharmacia, Saint-Quentin en Yve- hGH treatment. Height was expressed as the SD score (SDS) lines, France). IGF-I was measured by RIA, after acid gel for chronologic age (9). Weight for height was expressed as filtration (12). IGF-I antibody was kindly donated by Dr. P. body mass index [BMI = weight (kg)/height (m2)] in SD for Chatelain, Lyon, France. chronologic age (10). Growth velocities were calculated 12 mo Statistics. Results are expressed as mean + SEM. Statistical after beginning hGH therapy by subtracting the height at differences between groups were assessed using variance anal- baseline from the height at 12 mo. The clinical characteristics ysis. If overall significant differences were present, specific of patients are presented in Table 1. differences between two time periods were sought by the The 18 patients were investigated for biologic parameters Wilcoxon signed rank test (with a Bonferroni correction for before and 6, 12, and 24 mo after the onset of hGH treatment. simultaneity). The Mann-Whitney U test was used to compare The short-term response to the hGH treatment was evaluated in data in two different groups. Correlation between variables was 10 of them, and blood samples were collected before and at 6, evaluated by linear regression analysis. 12, 24, and 48 h, 8 d, and 1 and 3 mo after the beginning of treatment. For technical reasons, some blood samples could not RESULTS be obtained for all measurements. After the first 48 h of treatment, sampling was performed between 14 and 20 h after In 18 children with isolated GH deficiency, basal GHBP the last hormone injection. values were lower (14.6 + 1.2% of radioactivity, p < 0.001) Informed consent was obtained from the parents. than in normal prepubertal children (mean value in a group of Procedures. Blood samples were collected during the study 15 prepubertal normal children: 24.8 + 1.7%) (11). As shown period, and sera were stored at -20°C until assayed. Periodic in Table 2, values ranged from 7.0 to 25.4% of radioactivity. In samples were measured in the same assay. this group of prepubertal children, no relationship was found GHPB was measured by HPLC-gel filtration, as previously between GHBP levels and chronologic or bone age. However, described (11). Briefly, 100 pL of serum were incubated with a positive correlation was found between GHBP levels and 100 pL of potassium phosphate, 0.1 M, pH 7.0, containing BMI before treatment, as shown in Fig. 1 (r = 0.63, p = '"I-~GH (1 X lo5 cpm). After 20 h at 4OC, the incubation was 0.005). injected onto HPLC Protein Pak 300 sw column (Waters, GHBP and GH levels for 48 h after the first hGH injection Milford, MA). Elution was performed isocratically using de- are presented in Fig. 2. In the group of 10 children studied for gassed buffer pumped at a rate of 0.5 mWmin. Radioactivity the short-term hGH response, the GH peak at 6 h was associ- was recorded on line using a Berthold LB 504 y detector ated with a significant decrease in GHBP (p < 0.005). Both connected to a computer. To evaluate nonspecific binding, 2 GH and GHBP returned to baseline 24 h after the first hGH pg of hGH were added to the incubation. The binding of injection (Fig. 2 and Table 3). Under hGH treatment, an 125~-h~~is expressed as the percentage of total radioactivity increase in GHBP was observed in all patients but two (patients (radioactivity in the individual peak divided by total radioac- 10 and 14); however, in one patient GHBP could not be tivity in the peaks). The interassay coefficient of variation was assayed after 6 mo of treatment and in the other one, GHBP 8% (11). In some serum samples, the GH concentration was was normal before hGH therapy. Increase in GHBP occurred elevated, and the binding of 12'1-h~~to GHBP had to be slowly and at different times of GH therapy: in the group of 10 corrected for occupancy of the receptor by GH.
Load more

Recommended publications
  • Receptor-Mediated Dimerization of JAK2 FERM Domains Is Required for JAK2 Activation Ryan D Ferrao, Heidi JA Wallweber, Patrick J Lupardus*
    RESEARCH ARTICLE Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation Ryan D Ferrao, Heidi JA Wallweber, Patrick J Lupardus* Department of Structural Biology, Genentech, Inc., South San Francisco, United States Abstract Cytokines and interferons initiate intracellular signaling via receptor dimerization and activation of Janus kinases (JAKs). How JAKs structurally respond to changes in receptor conformation induced by ligand binding is not known. Here, we present two crystal structures of the human JAK2 FERM and SH2 domains bound to Leptin receptor (LEPR) and Erythropoietin receptor (EPOR), which identify a novel dimeric conformation for JAK2. This 2:2 JAK2/receptor dimer, observed in both structures, identifies a previously uncharacterized receptor interaction essential to dimer formation that is mediated by a membrane-proximal peptide motif called the ‘switch’ region. Mutation of the receptor switch region disrupts STAT phosphorylation but does not affect JAK2 binding, indicating that receptor-mediated formation of the JAK2 FERM dimer is required for kinase activation. These data uncover the structural and molecular basis for how a cytokine-bound active receptor dimer brings together two JAK2 molecules to stimulate JAK2 kinase activity. DOI: https://doi.org/10.7554/eLife.38089.001 Introduction Janus kinases (JAKs) are a family of multi-domain non-receptor tyrosine kinases responsible for pleio- tropic regulatory effects on growth, development, immune and hematopoietic signaling (Leonard and O’Shea, 1998). The JAK family consists of four conserved members, including JAK1, *For correspondence: [email protected] JAK2, JAK3, and TYK2, which are differentially activated in response to cytokine and interferon stim- ulation. JAKs are constitutively bound to the intracellular domains of their cognate cytokine signaling Competing interest: See receptors, and are activated after cytokine-mediated dimerization or rearrangement of these recep- page 18 tors establishes a productive receptor signaling complex (Haan et al., 2006).
    [Show full text]
  • Abstracts from the 9Th Biennial Scientific Meeting of The
    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
    [Show full text]
  • Program Nr: 1 from the 2004 ASHG Annual Meeting Mutations in A
    Program Nr: 1 from the 2004 ASHG Annual Meeting Mutations in a novel member of the chromodomain gene family cause CHARGE syndrome. L.E.L.M. Vissers1, C.M.A. van Ravenswaaij1, R. Admiraal2, J.A. Hurst3, B.B.A. de Vries1, I.M. Janssen1, W.A. van der Vliet1, E.H.L.P.G. Huys1, P.J. de Jong4, B.C.J. Hamel1, E.F.P.M. Schoenmakers1, H.G. Brunner1, A. Geurts van Kessel1, J.A. Veltman1. 1) Dept Human Genetics, UMC Nijmegen, Nijmegen, Netherlands; 2) Dept Otorhinolaryngology, UMC Nijmegen, Nijmegen, Netherlands; 3) Dept Clinical Genetics, The Churchill Hospital, Oxford, United Kingdom; 4) Children's Hospital Oakland Research Institute, BACPAC Resources, Oakland, CA. CHARGE association denotes the non-random occurrence of ocular coloboma, heart defects, choanal atresia, retarded growth and development, genital hypoplasia, ear anomalies and deafness (OMIM #214800). Almost all patients with CHARGE association are sporadic and its cause was unknown. We and others hypothesized that CHARGE association is due to a genomic microdeletion or to a mutation in a gene affecting early embryonic development. In this study array- based comparative genomic hybridization (array CGH) was used to screen patients with CHARGE association for submicroscopic DNA copy number alterations. De novo overlapping microdeletions in 8q12 were identified in two patients on a genome-wide 1 Mb resolution BAC array. A 2.3 Mb region of deletion overlap was defined using a tiling resolution chromosome 8 microarray. Sequence analysis of genes residing within this critical region revealed mutations in the CHD7 gene in 10 of the 17 CHARGE patients without microdeletions, including 7 heterozygous stop-codon mutations.
    [Show full text]
  • Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes
    Tohoku J. Exp. Med., 2011,Differential 223, 161-176 Gene Expression in OPCs, Oligodendrocytes and Type II Astrocytes 161 Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes Jian-Guo Hu,1,2,* Yan-Xia Wang,3,* Jian-Sheng Zhou,2 Chang-Jie Chen,4 Feng-Chao Wang,1 Xing-Wu Li1 and He-Zuo Lü1,2 1Department of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical College, Bengbu, P.R. China 2Anhui Key Laboratory of Tissue Transplantation, Bengbu Medical College, Bengbu, P.R. China 3Department of Neurobiology, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China 4Department of Laboratory Medicine, Bengbu Medical College, Bengbu, P.R. China Oligodendrocyte precursor cells (OPCs) are bipotential progenitor cells that can differentiate into myelin-forming oligodendrocytes or functionally undetermined type II astrocytes. Transplantation of OPCs is an attractive therapy for demyelinating diseases. However, due to their bipotential differentiation potential, the majority of OPCs differentiate into astrocytes at transplanted sites. It is therefore important to understand the molecular mechanisms that regulate the transition from OPCs to oligodendrocytes or astrocytes. In this study, we isolated OPCs from the spinal cords of rat embryos (16 days old) and induced them to differentiate into oligodendrocytes or type II astrocytes in the absence or presence of 10% fetal bovine serum, respectively. RNAs were extracted from each cell population and hybridized to GeneChip with 28,700 rat genes. Using the criterion of fold change > 4 in the expression level, we identified 83 genes that were up-regulated and 89 genes that were down-regulated in oligodendrocytes, and 92 genes that were up-regulated and 86 that were down-regulated in type II astrocytes compared with OPCs.
    [Show full text]
  • Blueprint of Pediatric Endocrinology Book
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/317428263 blueprint of pediatric endocrinology book Book · January 2014 CITATIONS READS 0 27 1 author: Abdulmoein Eid Al - Agha King Abdulaziz University 148 PUBLICATIONS 123 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: HYPOPHOSPHATEMIC RICKETS, EPIDERMAL NEVUS SYNDROME WITH... View project HYPERTRIGLYCERIDAEMIA-INDUCED ACUTE PANCREATITIS IN AN INFANT: A CASE REPORT View project All content following this page was uploaded by Abdulmoein Eid Al - Agha on 09 June 2017. The user has requested enhancement of the downloaded file. IN THE NAME OF ALLAH, THE MERCIFUL, THE MERCY-GIVING iii Blueprint in Pediatric Endocrinology Abdulmoein Eid Al-Agha, MBBS, DCH, FRCPCH Pediatric Endocrinologist King AbdulAziz University Faculty of Medicine Jeddah, Saudi Arabia © King Abdulaziz University: 1435 A.H. (2014 AD.) All rights reserved. 1st Edition: 1435 A.H. (2014 A.D.) Table of Contents Chapter 1: Basic Endocrinology Introduction…………………………………………………………………….. 3 Effects of hormones…………………………………………………………….. 3 Types of hormones……………………………………………………………… 4 Types of Hormone Receptors………………...………………………………... 5 Loss – of – function mutations………………………………………………….. 7 Gain – of – function mutations……………………………...………………….. 9 Fetal Brain Programming ………………………………………………………. 10 The endocrine system ……………………………...…………………………... 10 Hypothalamic-Pituitary Relationships………………………………………….. 10 Hypothalamic Controls………………………………………………………….
    [Show full text]
  • Childhood Growth and Puberty Delay Disorders
    Childhood Growth and Puberty Delay Disorders MAJ Craig Barstow, MD ACTIVITY DISCLAIMER The material presented here is being made available by the American Academy of Family Physicians for educational purposes only. Please note that medical information is constantly changing; the information contained in this activity was accurate at the time of publication. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations. The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application. This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP. 1 DISCLOSURE It is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflict of interest (COI), and if identified, conflicts are resolved prior to confirmation of participation. Only those participants who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this CME activity.
    [Show full text]
  • Incorrect Unit of Measure
    We agree with Berman that there may often be honest dif- (2) make the rationale public, and (3) provide opportunities for ferences of opinion among informed experts about the value of clinicians and members to appeal policies and specific deci- new treatments. As stated in our article, our study cannot sions.1 However, even in the outstanding programs we were establish whether current practices are right or wrong. How- privileged to study in our research on policymaking, we and ever, the wide gap between the recommendations of physi- the program leaders agreed there was room for significant cians and the approvals of insurers in the cases under study improvement. underscores a potentially far-reaching problem in the US Ms Tesch’s letter on behalf of the Turner’s Syndrome Soci- health care system. We believe that insurers often make very ety provides an example of well-conceived advocacy. The fact careful and fair analyses of information in arriving at coverage that GH has been recognized by the Food and Drug Admin- decisions.1 Nevertheless, greater dialogue between insurers istration as effective in the treatment of Turner syndrome and physicians is needed to minimize discrepancies in cover- puts a burden of explanation onto an insurer who chooses not age and to provide optimal patient care. to cover it. In asking whether decisions to deny coverage re- Dr Yaes asks about consensus among physicians for the flect “reasonable cost-benefit analysis or an inappropriate de- cases studied and about the value of a treatment such as GH, nial of care,” Tesch raises the key policy question in useful which is used for a non–life-threatening condition.
    [Show full text]
  • Pancancer IO360 Human Vapril2018
    Gene Name Official Full Gene name Alias/Prev Symbols Previous Name(s) Alias Symbol(s) Alias Name(s) A2M alpha-2-macroglobulin FWP007,S863-7,CPAMD5 ABCF1 ATP binding cassette subfamily F member 1 ABC50 ATP-binding cassette, sub-family F (GCN20),EST123147 member 1 ACVR1C activin A receptor type 1C activin A receptor, type IC ALK7,ACVRLK7 ADAM12 ADAM metallopeptidase domain 12 a disintegrin and metalloproteinase domainMCMPMltna,MLTN 12 (meltrin alpha) meltrin alpha ADGRE1 adhesion G protein-coupled receptor E1 TM7LN3,EMR1 egf-like module containing, mucin-like, hormone receptor-like sequence 1,egf-like module containing, mucin-like, hormone receptor-like 1 ADM adrenomedullin AM ADORA2A adenosine A2a receptor ADORA2 RDC8 AKT1 AKT serine/threonine kinase 1 v-akt murine thymoma viral oncogene homologRAC,PKB,PRKBA,AKT 1 ALDOA aldolase, fructose-bisphosphate A aldolase A, fructose-bisphosphate ALDOC aldolase, fructose-bisphosphate C aldolase C, fructose-bisphosphate ANGPT1 angiopoietin 1 KIAA0003,Ang1 ANGPT2 angiopoietin 2 Ang2 ANGPTL4 angiopoietin like 4 angiopoietin-like 4 pp1158,PGAR,ARP4,HFARP,FIAF,NL2fasting-induced adipose factor,hepatic angiopoietin-related protein,PPARG angiopoietin related protein,hepatic fibrinogen/angiopoietin-related protein,peroxisome proliferator-activated receptor (PPAR) gamma induced angiopoietin-related protein,angiopoietin-related protein 4 ANLN anillin actin binding protein anillin (Drosophila Scraps homolog), actin bindingANILLIN,Scraps,scra protein,anillin, actin binding protein (scraps homolog, Drosophila)
    [Show full text]
  • Wrap.Warwick.Ac.Uk/91754
    Original citation: Hu, Jiamiao and Christian, Mark. (2017) Hormonal factors in the control of the browning of white adipose tissue. Hormone Molecular Biology and Clinical Investigation. Permanent WRAP URL: http://wrap.warwick.ac.uk/91754 Copyright and reuse: The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions. Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available. Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. Publisher’s statement: “The final publication is available at www.degruyter.com ” http://dx.doi.org/10.1515/hmbci-2017-0017 A note on versions: The version presented here may differ from the published version or, version of record, if you wish to cite this item you are advised to consult the publisher’s version. Please see the ‘permanent WRAP URL’ above for details on accessing the published version and note that access may require a subscription. For more information, please contact the WRAP Team at: [email protected] warwick.ac.uk/lib-publications DE GRUYTER Hormone Molecular Biology and Clinical Investigation.
    [Show full text]
  • Guideline for the Diagnosis and Treatment of Celiac
    JOBNAME: gas 40#1 2005 PAGE: 1 OUTPUT: Wed December 15 18:39:15 2004 lww/gas/84141/MPG157309 Prod #: MPG157309 MS #xxx Journal of Pediatric Gastroenterology and Nutrition 40:1–19 Ó January 2005 Lippincott Williams & Wilkins, Philadelphia Clinical Guideline Guideline for the Diagnosis and Treatment of Celiac Disease in Children: Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition ABSTRACT The Committee examined the indications for testing, the value Celiac disease is an immune-mediated enteropathy caused by of serological tests, human leukocyte antigen (HLA) typing and a permanent sensitivity to gluten in genetically susceptible in- histopathology and the treatment and monitoring of children dividuals. It occurs in children and adolescents with gastroin- with celiac disease. It is recommended that children and ado- testinal symptoms, dermatitis herpetiformis, dental enamel lescents with symptoms of celiac disease or an increased risk defects, osteoporosis, short stature, delayed puberty and persis- for celiac disease have a blood test for antibody to tissue tent iron deficiency anemia and in asymptomatic individuals transglutaminase (TTG), that those with an elevated TTG be with type 1 diabetes, Down syndrome, Turner syndrome, Williams referred to a pediatric gastroenterologist for an intestinal biopsy syndrome, selective immunoglobulin (Ig)A deficiency and first and that those with the characteristics of celiac disease on degree relatives of individuals with celiac disease. The Celiac intestinal histopathology be treated with a strict gluten-free Disease Guideline Committee of the North American Society diet. This document represents the official recommendations of for Pediatric Gastroenterology, Hepatology and Nutrition has the North American Society for Pediatric Gastroenterology, formulated a clinical practice guideline for the diagnosis and Hepatology and Nutrition on the diagnosis and treatment of treatment of pediatric celiac disease based on an integration of celiac disease in children and adolescents.
    [Show full text]
  • Role of the Tyrosine Kinase JAK2 in Signal Transduction by Growth Hormone
    Pediatr Nephrol (2000) 14:550–557 © IPNA 2000 REVIEW ARTICLE Christin Carter-Su · Liangyou Rui James Herrington Role of the tyrosine kinase JAK2 in signal transduction by growth hormone Received: 15 May 1999 / Revised: 23 December 1999 / Accepted: 2 January 2000 Abstract Chronic renal failure in children results in im- Key words Growth · Growth hormone · JAK2 · Insulin paired body growth. This effect is so severe in some receptor substrates · Signal transducers and activators of children that not only does it have a negative impact on transcription · SH2-B their self-image, but it also affects their ability to carry out normal day-to-day functions. Yet the mechanism by which chronic renal failure causes short stature is not Introduction well understood. Growth hormone (GH) therapy increas- es body height in prepubertal children, suggesting that a As early as 1973 [1], growth hormone (GH) was recog- better understanding of how GH promotes body growth nized as binding to a membrane-bound receptor. Yet the may lead to better insight into the impaired body growth mechanism by which GH binding to its receptor elicits in chronic renal failure and therefore better therapies. the diverse responses to GH remained elusive for several This review discusses what is currently known about more decades. Even cloning of the GH receptor [2] in how GH acts at a cellular level. The review discusses 1987 did not shed light on the mechanism by which the how GH is known to bind to a membrane-bound receptor GH receptor functioned, because the deduced amino acid and activate a cytoplasmic tyrosine kinase called Janus sequence of the cloned rabbit and human liver GH recep- kinase (JAK) 2.
    [Show full text]
  • A Bifunctional Fusion Protein Bridging Natural Killer Cells and PRLR-Positive Breast Cancer Cells
    Clemson University TigerPrints All Dissertations Dissertations August 2020 MICA-G129R: A Bifunctional Fusion Protein Bridging Natural Killer Cells and PRLR-positive Breast Cancer Cells Hui Ding Clemson University, [email protected] Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations Recommended Citation Ding, Hui, "MICA-G129R: A Bifunctional Fusion Protein Bridging Natural Killer Cells and PRLR-positive Breast Cancer Cells" (2020). All Dissertations. 2690. https://tigerprints.clemson.edu/all_dissertations/2690 This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by an authorized administrator of TigerPrints. For more information, please contact [email protected]. MICA-G129R: A BIFUNCTIONAL FUSION PROTEIN BRIDGING NATURAL KILLER CELLS AND PRLR-POSITIVE BREAST CANCER CELLS A Dissertation Presented to the Graduate School of Clemson University In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy Biological Sciences by Hui Ding August 2020 Accepted by: Dr. Yanzhang Wei, Committee Chair Dr. Charles D. Rice Dr. Lesly A. Temesvari Dr. Tzuen-Rong Tzeng i ABSTRACT Breast cancer is the most common diagnosed and deathly cancer in women all over the world. Besides the conventional cancer therapy, based on the receptors expressed in breast cancer, hormone therapy targeting estrogen receptors (ER) and progesterone receptors (PR), and targeted therapy using antibodies or inhibitors targeting human epidermal growth factor receptor 2 (HER2) are the common and standard treatments for breast cancer. However, breast cancer is a highly heterogeneous disease. About 15-20% of breast cancers do not significantly express the three receptors, which are classified as the triple-negative breast cancer and the most dangerous type of breast cancer because of lack of effective targets for treatment.
    [Show full text]